Answer:
A couple treatment plans include:
Thrombolytic
Parenteral Anticoagulation
Intravenous UFH
Oral Anticoagulation
And Aspirin
Explanation:
Thrombolytic:
Patients with massive PE who are not at high risk of bleeding are candidates for systemic thrombolytic therapy with alteplase, also known as tissue plasminogen activator (tPA).
Parenteral Anticoagulation:
May be used alone in patients who are not candidates for tPA, or are initiated at the end of the tPA infusion.12,19 These medications prevent further clot formation and work in the coagulation cascade to enhance the body’s ability to dissolve existing clots.
Intravenous UFH:
The treatment of choice for patients at high risk of bleeding or who are likely to undergo intervention, thrombolysis, or embolectomy, owing to its short half-life.
Oral Anticoagulation:
The 2016 antithrombotic guidelines recommend oral anticoagulation with direct oral anticoagulants (DOACs): direct thrombin inhibitor dabigatran, or factor Xa inhibitors edoxaban, rivaroxaban, or apixaban in low-risk patients without cancer.
Aspirin:
Three studies evaluated the use of aspirin for extended treatment. The authors concluded that aspirin reduced the overall risk of recurrence of unprovoked PE without increased risk of bleeding when compared with placebo.
May be considered for extended treatment in patients who are stopping anticoagulation and have no contraindications to aspirin.
SORRY FOR THE LONG MESSAGE. I HOPE THIS HELPED!! <333
